RXi Pharmaceuticals (RXII) Earning Somewhat Favorable Press Coverage, Report Finds

Press coverage about RXi Pharmaceuticals (NASDAQ:RXII) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. RXi Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.8647874186283 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

RXi Pharmaceuticals (RXII) opened at $4.50 on Wednesday. The company has a market cap of $10.17, a PE ratio of -0.41 and a beta of 1.38. RXi Pharmaceuticals has a 52-week low of $3.20 and a 52-week high of $11.20.

RXi Pharmaceuticals (NASDAQ:RXII) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($1.10) EPS for the quarter, meeting the Zacks’ consensus estimate of ($1.10). During the same quarter last year, the business posted ($3.40) EPS.

TRADEMARK VIOLATION WARNING: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://baseballnewssource.com/markets/rxi-pharmaceuticals-rxii-receiving-somewhat-favorable-press-coverage-report-shows/1822555.html.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.